Abbott Laboratories (ABT) - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0028241000

(NYSE:ABT Stock) Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois. Web URL: https://www.abbott.com

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Abbott Laboratories (ABT) - Stock Price & Dividends

ABT Stock Overview

Market Cap in USD 194,630m
Sector Healthcare
Industry Medical Devices
GiC SubIndustry Health Care Equipment
TER 0.00%
IPO / Inception 1978-01-13

ABT Stock Ratings

Fundamental 2.56
Dividend 8.13
Growth 5y 4.12
Rel. Performance vs Sector 0.02
Analysts 4.21
Fair Price Total Ret. 112.85
Fair Price DCF 42.97

ABT Dividends

Yield 12m 1.76%
Yield on Cost 5y 2.94%
Dividends CAGR 5y 9.77%
Payout Consistency 98.4%

ABT Growth Ratios

Growth 12m 17.11%
Growth Correlation 12m 19%
Growth Correlation 3m 74%
CAGR 5y 10.76%
CAGR / Mean Drawdown 0.90
Sharpe Ratio 12m 0.61
Alpha vs SP500 12m -5.69
Beta vs SP500 5y weekly 0.82
CAPM 7.50%
Average Daily Range 2m 1.48%
Regime Oscillator 85.20
Volatility GJR Garch 1y 20.56%
Price / SMA 50 5.88%
Price / SMA 200 13.14%
Current Volume 6144.8k
Average Volume 20d 6007.1k

External Links for ABT Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
X (Twitter)Stocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of ABT stocks?
As of February 22, 2024, the stock is trading at USD 117.87 with a total of 6,144,814 shares traded.
Over the past week, the price has changed by +5.18%, over one month by +3.22%, over three months by +16.22% and over the past year by +16.03%.
Why is ABT stock down?
Check with which Index or Commodity ABT has the highest Correlation, do they have a common driver?
Review the Fundamentals to find weaknesses (Debt, low returns). Check the Performance of the Peer-Group to find out, if the entire sector is under pressure.
Period Return ABT Return S&P 500
1 Month 3.22% 2.85%
3 Months 16.22% 10.14%
12 Months 16.03% 26.48%
What is the forecast for ABT stock price target?
According to ValueRays Forecast Model, ABT Abbott Laboratories will be worth about 122.7 in February 2025. The stock is currently trading at 117.87. This means that the stock has a potential upside of +4.06%.
Issuer Forecast Upside
Wallstreet Target Price 125.4 6.4%
Analysts Target Price 110.7 -6.1%
ValueRay Target Price 122.7 4.1%